黄曜,朱鲜阳

• 1:中国人民解放军原沈阳军区总医院先心病内科

摘要(Abstract)：

<正>先天性心脏病(congenital heart disease,CHD)指在胚胎发育时期由于心脏及大血管的形成障碍或发育异常而引起的解剖结构异常,或出生后应自动关闭的通道未能闭合(在胎儿属正常)的情形。根据血流动力学结合病理生理变化,CHD分为发绀型和非发绀型,也可根据有无分流分为三类:(1)无分流类,如肺动脉狭窄(pulmonary stenosis,PS)、主动脉缩窄;(2)左至右分流类,如房间隔缺损(atrial septal

关键词(KeyWords)： 先天性心脏病;经导管封堵;生物可吸收;生物可降解;封堵器

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学技术基金面上项目(81370276)

作者(Author): 黄曜,朱鲜阳

参考文献(References)：

• [1]Matter M,Almarsafawy H,Hafez M,et al.Balloon atrial septostomy:The oldest cardiac interventional procedure in Mansoura.Egyptian Heart J,2011,63(2):125-129.
• [2]Chaput U,Vienne A,Audureau E,et al.Temporary placement of fully covered self-expandable metal stents for the treatment of benign biliary strictures.United European Gastroenterol J,2016,4(3):403-412.
• [3]Jiang L,Zhang J.Biodegradable and Biobased Polymers-Applied Plastics Engineering Handbook-9.USA:William Andrew Publishing,2011:145-158.
• [4]Bartkowiak-Jowsa M,Bdziński R,Szaraniec B,et al.Mechanical,biological,and microstructural properties of biodegradable models of polymeric stents made of PLLA and alginate fibers.Acta Bioeng Biomech,2011,13(4):21-28.
• [5]Huang J,Zhang H,Yu Y,et al.Biodegradable self-assembled nanoparticles of poly(D,L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer.Biomaterials,2014,35(1):550-566.
• [6]Day M,Cooney JD,Shaw K,et al.Thermal analysis of some environmentally degradable polymers.J Thermal Analysis Calorimetry,1998,52(2):261-274.
• [7]Ji HP,Kang HJ,Kwon DY,et al.Biodegradable poly(lactideco-glycolide-co-ε-caprolactone)block copolymers-evaluation as drug carriers for a localized and sustained delivery system.J Mater Chem B,2015,3(41):8143-8153.
• [8]Hyung Sup Kim,Seung Hoon Um,Sang Hoon Rhee.The evaluation of hydroxyl ions as a nucleating agent for apatite on electrospun non-woven poly(ε-caprolactone)fabric.J Biomater Sci Polym Ed,2011,10(1):67-72.
• [9]He X,Kawazoe N,Chen G.Preparation of cylinder-shaped porous sponges of poly(L-lactic acid),poly(DL-lactic-coglycolic acid),and poly(ε-caprolactone).Biomed Res Int,2014,2014:106082.
• [10]Yang CS,Wu HC,Sun JS,et al.Thermo-induced shape-memory PEG-PCL copolymer as a dual-drug-eluting biodegradable stent.ACS Appl Mater Interfaces,2013,5(21):10985-10994.
• [11]Lowry KJ,Hamson KR,Bear L,et al.Polycaprolactone/glass bioabsorbable implant in a rabbit humerus fracture model.J Biomed Mater Res,1997,36(4):536-541.
• [12]Rohner D,Hutmacher DW,See P,et al.Individually CAD-CAM technique designed,hioresoibahle 3-dimensional polycaprolactone framework for experimental reconstruction of craniofacial defects in the pig.Mund Kiefer Gesiclitschir,2002,6(3):162-167.
• [13]Freudenberg S,Rewerk S,Kaess M,et al.Biodegradation of absorbable sutures in body fluids and p H buffers.Eur Surg Res.2004,36(6):376-385.
• [14]Zilberman M,Nelson KD,Eberhart RC,et al.Mechanical propertiesand in vitro degradation of bioresorbable fibers and expandable fiber-based stents.J Biomed Mater Res B Appl Biomater,2005,74(2):792-799.
• [15]Huang K,Ding X,Lv B,et al.Reconstruction of large-size abdominal wall defect using biodegradable poly-p-dioxanone mesh:an experimental canine study.World J Surg Oncol,2014,12:57.
• [16]Sreedevi S,Unni KN,Sajith S,et al.Bioplastics:advances in polyhydroxybutyrate research.Germany:Springer Berlin Heidelberg.2014:1-30.
• [17]Sibbons PD,Pullan RD,Brás LEDC.Biopsies of PermacolTM implant in humans after use in abdominal wall repair:histological and immunohistochemical analysis.Comp Clin Pathol,2015,24(4):831-840.
• [18]Rong JJ,Sang HF,Qian AM,et al.Biocompatibility of porcine small intestinal submucosa and rat endothelial progenitor cells in vitro.Int J Clin Exp Pathol,2015,8(2):1282-1291.
• [19]Jux C,Bertram H,Wohlsein P,et al.Interventional atrial septal defect closure using a totally bioresorbable occluder matrix:development and preclinical evaluation of the Bio STAR device.J Am Coll Cardiol,2006,48(1):161-169.
• [20]Kimmelstiel C.Here today,gone tomorrow:percutaneous closure of atrial septal defects utilizing a bioabsorbable device.Catheter Cardiovasc Interv,2010,76(2):246.
• [21]Mullen MJ,Hildick-Smith D,De Giovanni JV,et al.Bio STAR evaluation study(BEST):a prospective,multicenter,phase I clinical trial to evaluate the feasibility,efficacy,and safety of the Bio STAR bioabsorbable septal repair implant for the closure of atrial-level shunts.Circulation,2006,114(18):1962-1967.
• [22]Morgan G,Lee KJ,Chaturvedi R,et al.A biodegradable device(Bio STAR)for atrial septal defect closure in children.Catheter Cardiovasc Interv,2010,76(2):241-245.
• [23]Hoehn R,Hesse C,Ince H,et al.First experience with the Bio STAR-device for various applications in pediatric patients with congenital heart disease.Catheter Cardiovasc Interv,2010,75(1):72-77.
• [24]Baspinar O,Kervancioglu M,Kilinc M,et al.Bioabsorbable atrial septal occluder for percutaneous closure of atrial septal defect in children.Tex Heart Inst J,2012,39(2):184-189.
• [25]Jux C,Bertram H.Thrombus formation on intracardiac devices:a complex issue.J Am Coll Cardiol,2004,44(8):1712-1713.
• [26]Butera G,Carminati M,Chessa M,et al.Cardio SEAL/STARflex versus Amplatzer devices for percutaneous closure of small to moderate(up to 18 mm)atrial septal defects.Am Heart J,2004,148(3):507-510.
• [27]Cikirikcioglu M,Cherian S,Lerch R,et al.Late tamponade secondary to aortic root perforation by biostar septal closure device.Ann Thorac Surg,2011,91(2):604-606.
• [28]Chessa M,Carminati M,Butera G,et al.Early and late complications associated with transcatheter occlusion of secundum atrial septal defect.J Am Coll Cardiol,2002,39(6):1061-1065.
• [29]Ussia GP,Cammalleri V,MulèM,et al.Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device:single-centre experience.Catheter Cardiovasc Interv,2009,74(4):607-614.
• [30]Duong-Hong D,Tang YD,Wu W,et al.Fully degradable septal defect occluder-a double umbrella design.Catheter Cardiovasc Interv,2010,76(5):711-718.
• [31]Yin W,Jo H,Voit EO.Systems analysis of the role of bone morphogenic protein 4 in endothelial inflammation.Ann Biomed Eng,2010,38(2):291-307.
• [32]Nieswandt B,Pleines I,Bender M.Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke.J Thromb Haemost,2011,9 Suppl 1:92-104.
• [33]Xie J,Ihara M,Jung Y,et al.Mechano-active scaffold design based on microporous poly(L-lactide-co-epsilon-caprolactone)for articular cartilage tissue engineering:dependence of porosity on compression force applied mechanical behaviors.Tissue Eng,2006,12(3):449-458.
• [34]Liu SJ,Peng KM,Hisao CY,et al.Novel biodegradable polycaprolactone occlusion device combining nanofibrous PLGA/collagen membrane for closure of atrial septal defect(ASD).Ann Biomed Eng,2011,39(11):2759-2766.
• [35]Tamura H,Watanabe T,Hirono O,et al.Low wall velocity of left atrial appendage measured by trans-thoracic echocardiography predicts thrombus formation caused by atrial appendage dysfunction.J Am Soc Echocardiogr,2010,23(5):545-552.
• [36]Zhu YF,Huang XM,Cao J,et al.Animal experimental study of the fully biodegradable atrial septal defect(ASD)occluder.J Biomed Biotechnol,2012,2012:735989.
• [37]Woodruff MA,Hutmacher DW.The return of a forgotten polymerpolycaprolactone in the 21st century.Prog Polym Sci,2010,35(10):1217-1256.
• [38]戴柯,李奋,孙康,等.全生物可降解型房间隔缺损封堵器封堵猪房间隔缺损的实验研究.临床儿科杂志,2010,28(4):375-379.
• [39]Huang YY,Wong YS,Chan JN,et al.A fully biodegradable patent ductus arteriosus occlude.J Mater Sci Mater Med,2015,26(2):93.
• [40]King TD,Thompson SL,Steiner C,et al.Secundum atrial septal defect:Nonoperative closure during cardiac catheterization.JAMA,1976,235(23):2506-2509.